Results 21 to 30 of about 164,343 (265)
Exploring the clinicopathological parameters of HER2 low breast cancers: insights from a retrospective cohort study [PDF]
Korean Journal of Clinical OncologyPurpose Breast cancer subtypes are delineated by human epidermal growth factor receptor 2 (HER2) expression, pivotal in treatment selection. HER2-positive tumors typically respond to targeted therapies, whereas HER2-negative tumors lack HER2 ...
Sana Ahuja +3 more
doaj +1 more source
The molecular landscape of breast mucoepidermoid carcinoma
Cancer Medicine, 2023 Mucoepidermoid carcinoma (MEC) of the breast is an extremely rare salivary gland‐type tumor characterized by epidermoid, basaloid, intermediate, and/or mucinous cells arranged in solid and cystic patterns.
Konstantinos Venetis +15 more
doaj +1 more source
Cureus, 2022 Triple-negative breast cancer (TNBC) has been extensively studied not just for its aggressive behavior but also to understand its complex molecular nature.
Lisbeth Escudero Mendez +7 more
semanticscholar +1 more source
Cellular Oncology, 2022 The transcriptional repressor B-cell lymphoma 6 (BCL6) is dysregulated in several neoplasms, but its role in triple negative breast cancer (TNBC), a highly aggressive subtype which lacks effective treatment, is unclear.
F. De Santis +9 more
semanticscholar +1 more source
International Journal of Molecular Sciences, 2022 Metabolic dysregulation as a reflection of specific metabolite production and its utilization is a common feature of many human neoplasms. Melatonin, an indoleamine that is highly available during darkness, has a variety of metabolic functions in solid ...
R. P. Junior +6 more
semanticscholar +1 more source
Immunotherapy in triple-negative breast cancer: mechanisms of resistance and emerging approaches: a narrative review [PDF]
Journal of Yeungnam Medical ScienceTriple-negative breast cancer (TNBC) is characterized by less treatment responsiveness and poorer prognosis than other breast cancer subtypes. The introduction of anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunotherapy ...
Sung Ae Koh
doaj +1 more source
High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy [PDF]
Journal of Pathology and Translational Medicine, 2018 Background Chemokine receptor CXC chemokine receptor type 4 (CXCR4) and its ligand CXC motif chemokine 12 (CXCL12; stromal cell-derived factor-1) are implicated in tumor growth, metastasis, and tumor cell-microenvironment interaction. A number of studies
Bobae Shim +4 more
doaj +1 more source
Expression of SOX10 in Triple-Negative Breast Carcinoma in Pakistan
Cureus, 2022 Background The term triple-negative breast cancer (TNBC) refers to a particular class of aggressive, poorly differentiated neoplasms that show the absence of estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2) antibodies.
Seema Ali +4 more
semanticscholar +1 more source
Virchows Archiv, 2021 Triple-negative breast carcinomas constitute a wide spectrum of lesions, mostly being highly aggressive. Nevertheless, some special histologic subtypes can have low malignant potential.
L. Cima +6 more
semanticscholar +1 more source
Results of clinical developments of early triple negative breast cancer drug treatment: ASCO - 2022
City Healthcare, 2022 Introduction. This article continues the series of reviews of innovative clinical developments related to drug therapy for leading cancers following the ASCO-2022 Annual Congress.
D. Andreev, A. Zavyalov
semanticscholar +1 more source